Substance
IVACAFTOR
Global reference: every product and company linked to this substance.
- cas: 873054-44-5
- ncit: C166523
- pubchem_cid: 16220172
- rxnorm: 1243041
- unii: 1Y740ILL1Z
Ivacaftor [INN] · Ivacaftor [USAN] · Ivacaftor [WHO-DD] · Kalydeco · ORKAMBI COMPONENT IVACAFTOR · SYMKEVI COMPONENT IVACAFTOR · TRIKAFTA COMPONENT IVACAFTOR · VX-770
Revenue by product (4)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK | TRIKAFTA (COPACKAGED) | Q2 2026 | $2.5B* |
| VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK | KALYDECO | Q4 2023 | $112.4M |
| VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK | ORKAMBI | Q4 2023 | $44.2M* |
| VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK | SYMDEKO (COPACKAGED) | Q4 2023 | $27.8M* |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (4)
- KALYDECO · VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK
- ORKAMBI · VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK
- SYMDEKO (COPACKAGED) · VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK
- TRIKAFTA (COPACKAGED) · VERTEX PHARMACEUTICALS INCORPORATED COMMON STOCK